Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk0686. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 known ✓ | P46663 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk0686 SCHEMBL1713029 | 1.00 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL9947991 | 0.93 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL1713230 | 0.92 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL13449215 | 0.92 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL6184735 | 0.91 | BDKRB1 (0.84) | BDKRB1 | |
| SCHEMBL6185454 | 0.88 | BDKRB1 (0.79) | BDKRB1 | |
| SCHEMBL13449147 | 0.86 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL1712917 | 0.86 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4983157 | 0.84 | BDKRB1 (0.78) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL6183823 | 0.83 | BDKRB1 (0.71) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| CN-118206634-A | Ligand-regulated protein-protein interaction system | 圣安娜儿童癌症研究中心 | 2024-06-18 | — | — | CN | claimed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | claimed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | claimed |
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | claimed |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-04 | — | — | US | disclosed |
| CN-115068468-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| CN-115137726-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| CN-118206634-A | Ligand-regulated protein-protein interaction system | 圣安娜儿童癌症研究中心 | 2024-06-18 | — | — | CN | disclosed |
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-20 | — | — | US | disclosed |
| US-20120202744-A1 | DUAL ANTAGONISM OF ENDOTHELIN TYPE A AND BRADYKININ B1 RECEPTORS FOR TREATING PAIN AND PREVENTING CARTILAGE DEGRADATION | MOLDOVAN FLORINA (CA) | 2012-08-09 | — | — | US | disclosed |
| US-20120202744-A1 | DUAL ANTAGONISM OF ENDOTHELIN TYPE A AND BRADYKININ B1 RECEPTORS FOR TREATING PAIN AND PREVENTING CARTILAGE DEGRADATION | MOLDOVAN FLORINA (CA) | 2012-08-09 | — | — | US | disclosed |
| WO-2010031577-A1 | USE OF BRADYKININ B1 RECEPTOR ANTAGONISTS IN INTESTINAL FIBROSIS TREATMENT | JERINI AG (DE) | 2010-03-25 | — | — | WO | disclosed |
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | WOOD MICHAEL R (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK SHARP & DOHME LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | BDKRB1 1/4885 |
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | BDKRB1 1997/4885 |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | BDKRB1 1/4885 |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885 |
| US-20120202744-A1 | DUAL ANTAGONISM OF ENDOTHELIN TYPE A AND BRADYKININ B1 RECEPTORS FOR TREATING PAIN AND PREVENTING CARTILAGE DEGRADATION | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885 |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.